Accessibility helpSkip to navigationSkip to main contentSkip to footer Discover how the midterms will shape policy, markets and the global economy with expert FT analysis. Discover how the midterms will shape policy, markets and the global economy with expert FT analysis. Potential spin-off of drugstore business comes as political pressure mounts on pharmacy benefit managers and health insurers CVS has led the charge as the wider health insurance industry emerges from a period of financial strain, with cost controls boosting margins© Jeff Greenberg/Universal Images/Getty Images Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
CVS Health is plotting a break-up of its $117bn healthcare empire, separating its retail pharmacy chain from its insurance business in what would be one of the largest corporate splits of all time. The move would unwind CVS’s $78bn acquisition of health insurance company Aetna in 2018, which created a vertically integrated healthcare conglomerate spanning an insurer, a pharmacy benefit manager and a retail pharmacy. Under plans being discussed, CVS would spin off its retail pharmacy division, whose 9,000 drugstores are projected to generate a third of the group’s $417bn in revenue this year, as a separate listed company, according to people familiar with the matter.
The break-up would come as the industry faces intense political pressure challenging combined ownership of PBMs, which manage drug prescription benefits on behalf of insurers, employers and pharmacies. The company could announce the move as early as its third-quarter results this week, the people said. Insurer Aetna and Caremark, CVS’s PBM, would remain together under one corporate entity as part of the plans under consideration, they added.
The structure and timeline of the break-up were still in flux and could yet change, the people warned. CVS did not immediately respond to a request for comment. Shares in CVS have bounced back under the leadership of David Joyner, who started as chief executive in October 2024, driven by a turnaround at its Aetna insurance unit.
Its stock sank to a 10-year low in December 2024. CVS’s market value stood at $116.9bn at Tuesday’s close, more than double where it was trading at its nadir. CVS is fighting states’ legislation to ban companies from owning PBMs and pharmacies.
Lawmakers in Arkansas and Tennessee were the first two states to introduce such measures. Earlier this year, Tennessee’s state legislature passed the Fair Rx Act banning ownership of pharmacies by companies which run both a PBM and insurer. CVS and its rival Cigna have sued to try to block the measure, which is set to take effect in 2028.
Extract — continue reading at the source.
